<DOC>
	<DOCNO>NCT01007591</DOCNO>
	<brief_summary>An international , multi-centre , prospective , randomised , double-blind , active-controlled , 2-arm , parallel group , 8-week , phase 3 clinical study paediatric patient ( age 6 17 year ) psoriasis vulgaris face intertriginous area</brief_summary>
	<brief_title>A Study Comparing LEO 80190 Ointment With Hydrocortisone Ointment , Both Applied Once Daily Treatment Psoriasis Vulgaris Face Intertriginous Areas</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Clinical diagnosis psoriasis vulgaris involve face Clinical sign psoriasis vulgaris trunk and/or limb , early diagnose psoriasis vulgaris trunk and/or limb . The extent severity psoriasis vulgaris trunk and/or limbs amenable topical therapy allow medication An extent psoriatic involvement face least 5 cm2 ( sum facial lesion ) Treatment area ( face intertriginous area ) amenable topical treatment maximum 30 g ( 6 11 year ) 45 g ( 12 17 year ) ointment per week Disease severity grade mild , moderate severe accord investigator 's global assessment disease severity face Aged 6 17 year Systemic treatment therapy biologicals potential effect psoriasis vulgaris within 4week period prior randomisation Systemic treatment biological therapy ( market market ) possible effect psoriasis vulgaris within 4 week ( etanercept ) , 2 month ( adalimumab , alefacept , infliximab ) , 4 month ( ustekinumab ) 4 weeks/5 halflives ( whichever longer ) experimental biological product prior randomisation PUVA therapy Grenz ray therapy within 4week period prior randomisation UVB therapy within 2week period prior randomisation Topical treatment psoriasis vulgaris lesion face intertriginous area within 2week period prior randomisation Topical treatment potent WHO group IV corticosteroid within 2week period prior randomisation Initiation expect change concomitant medication may affect psoriasis vulgaris ( e.g. , beta blocker , antimalaria drug , lithium ACE inhibitor ) treatment phase study Current diagnosis erythrodermic , exfoliative pustular psoriasis</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>